MARKETABLE SECURITIES |
3 Months Ended |
|---|---|
Dec. 31, 2022 | |
| Marketable Securities [Abstract] | |
| MARKETABLE SECURITIES | NOTE 3 – MARKETABLE SECURITIES
During the fiscal year ended 2017, the Company acquired shares of common stock of Amarantus BioScience Holdings, Inc. (“AMBS”) with a fair value of $40,980. The AMBS common stock is recorded as marketable securities in the accompanying balance sheets. Its fair value is adjusted every reporting period and the change in fair value is recorded in the statements of operations as unrealized gain or (loss) on marketable securities. During the three months ended December 31, 2022 and 2021, the Company recorded $(2,000) and $5,400 of unrealized (loss) gain on marketable securities, respectively. As of December 31, 2022 and September 30, 2022, the fair value of these shares was $1,700 and $3,700, respectively.
|